Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis.

Bhattacharyya S, Wang W, Tamaki Z, Shi B, Yeldandi A, Tsukimi Y, Yamasaki M, Varga J.

Front Immunol. 2018 Oct 23;9:2434. doi: 10.3389/fimmu.2018.02434. eCollection 2018.

2.

Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.

Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Toyama T, Takahashi T, Ichimura Y, Noda S, Akamata K, Saigusa R, Miyazaki M, Kuwano Y, Yanaba K, Yoshizaki A, Sato S.

J Dermatol. 2018 Dec;45(12):1425-1433. doi: 10.1111/1346-8138.14669. Epub 2018 Oct 5.

PMID:
30289572
3.

Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients.

Matsuda R, Yamamichi N, Shimamoto T, Sumida H, Takahashi Y, Minatsuki C, Kodashima S, Ono S, Niimi K, Tsuji Y, Sakaguchi Y, Saito I, Kataoka Y, Asada-Hirayama I, Kakimoto H, Yakabi S, Takeuchi C, Matsumoto Y, Tamaki Z, Fujishiro M, Asano Y, Sato S, Koike K.

Digestion. 2018;98(4):201-208. doi: 10.1159/000489848. Epub 2018 Jul 25.

PMID:
30045036
4.

TLR4-dependent fibroblast activation drives persistent organ fibrosis in skin and lung.

Bhattacharyya S, Wang W, Qin W, Cheng K, Coulup S, Chavez S, Jiang S, Raparia K, De Almeida LMV, Stehlik C, Tamaki Z, Yin H, Varga J.

JCI Insight. 2018 Jul 12;3(13). pii: 98850. doi: 10.1172/jci.insight.98850.

5.

Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.

Sato S, Kanbe T, Tamaki Z, Furuichi M, Uejima Y, Suganuma E, Takano T, Kawano Y.

Pediatr Int. 2018 Aug;60(8):697-702. doi: 10.1111/ped.13613. Epub 2018 Jul 30.

PMID:
29888432
6.

Systemic sclerosis complicated with localized scleroderma-like lesions induced by Köbner phenomenon.

Saigusa R, Asano Y, Yamashita T, Takahashi T, Nakamura K, Miura S, Ichimura Y, Toyama T, Taniguchi T, Sumida H, Tamaki Z, Miyazaki M, Yoshizaki A, Sato S.

J Dermatol Sci. 2018 Mar;89(3):282-289. doi: 10.1016/j.jdermsci.2017.12.005. Epub 2017 Dec 16.

PMID:
29279288
7.

A possible implication of reduced levels of LIF, LIFR, and gp130 in vasculopathy related to systemic sclerosis.

Taniguchi T, Miyagawa T, Tamaki Z, Nakamura K, Yamashita T, Saigusa R, Takahashi T, Toyama T, Ichimura Y, Yoshizaki A, Tada Y, Sugaya M, Kadono T, Sato S, Asano Y.

Arch Dermatol Res. 2017 Dec;309(10):833-842. doi: 10.1007/s00403-017-1786-4. Epub 2017 Oct 16.

PMID:
29038846
8.

Efficacy and safety of oral propranolol for infantile hemangioma in Japan.

Kaneko T, Sasaki S, Baba N, Koh K, Matsui K, Ohjimi H, Hayashi N, Nakano A, Ohki K, Kuwano Y, Morimoto A, Tamaki Z, Kakazu M, Kishi K, Oyama T, Sato A, Kato R, Higuchi T.

Pediatr Int. 2017 Aug;59(8):869-877. doi: 10.1111/ped.13318. Epub 2017 Jun 30.

PMID:
28453894
9.

Ethosuximide-induced lupus-scleroderma syndrome with disease-specific autoantibodies.

Toyama T, Asano Y, Taniguchi T, Takahashi T, Ichimura Y, Tamaki Z, Kagami S, Mitsui H, Sato S.

Eur J Dermatol. 2017 Apr 1;27(2):196-197. doi: 10.1684/ejd.2016.2942. No abstract available.

PMID:
28026802
10.

Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.

Saigusa R, Asano Y, Nakamura K, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Yoshizaki A, Miyazaki M, Tamaki Z, Sato S.

Mod Rheumatol. 2017 Jul;27(4):618-622. doi: 10.1080/14397595.2016.1226472. Epub 2016 Sep 13.

PMID:
27538472
11.

Tenascin-C drives persistence of organ fibrosis.

Bhattacharyya S, Wang W, Morales-Nebreda L, Feng G, Wu M, Zhou X, Lafyatis R, Lee J, Hinchcliff M, Feghali-Bostwick C, Lakota K, Budinger GR, Raparia K, Tamaki Z, Varga J.

Nat Commun. 2016 Jun 3;7:11703. doi: 10.1038/ncomms11703.

12.

A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis.

Takahashi T, Asano Y, Nakamura K, Yamashita T, Saigusa R, Ichimura Y, Toyama T, Taniguchi T, Yoshizaki A, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

Br J Dermatol. 2016 Dec;175(6):1195-1203. doi: 10.1111/bjd.14699. Epub 2016 Aug 30.

PMID:
27105895
13.

Association of anti-RNA polymerase III antibody and silicone breast implants in patients with systemic sclerosis.

Saigusa R, Asano Y, Nakamura K, Yamashita T, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Yoshizaki A, Miyazaki M, Tamaki Z, Sato S.

J Dermatol. 2016 Jul;43(7):808-10. doi: 10.1111/1346-8138.13292. Epub 2016 Feb 15.

PMID:
26876001
14.

Scleroderma en coup de sabre with recurrent episodes of brain hemorrhage.

Takahashi T, Asano Y, Oka T, Miyagaki T, Tamaki Z, Nonaka S, Sato S.

J Dermatol. 2016 Feb;43(2):203-6. doi: 10.1111/1346-8138.13023. Epub 2015 Jul 15.

PMID:
26173737
15.

Serum omentin levels: A possible contribution to vascular involvement in patients with systemic sclerosis.

Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T.

J Dermatol. 2015 May;42(5):461-6. doi: 10.1111/1346-8138.12824. Epub 2015 Mar 13.

PMID:
25766303
16.

Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis.

Saigusa R, Asano Y, Nakamura K, Miura S, Ichimura Y, Takahashi T, Toyama T, Taniguchi T, Noda S, Aozasa N, Akamata K, Sumida H, Miyazaki M, Tamaki Z, Yanaba K, Kuwano Y, Sato S.

J Dermatol. 2015 May;42(5):524-7. doi: 10.1111/1346-8138.12827. Epub 2015 Feb 27.

PMID:
25720827
17.

Serum vaspin levels: A possible correlation with digital ulcers in patients with systemic sclerosis.

Miura S, Asano Y, Saigusa R, Yamashita T, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T.

J Dermatol. 2015 May;42(5):528-31. doi: 10.1111/1346-8138.12810. Epub 2015 Feb 24.

PMID:
25708680
18.

A possible contribution of endothelial CCN1 downregulation due to Fli1 deficiency to the development of digital ulcers in systemic sclerosis.

Saigusa R, Asano Y, Taniguchi T, Yamashita T, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

Exp Dermatol. 2015 Feb;24(2):127-32. doi: 10.1111/exd.12602.

PMID:
25421497
19.

Development of systemic sclerosis in patients with Behçet's disease: remission of Behçet's disease in parallel with the progression of skin sclerosis.

Ichimura Y, Asano Y, Takahashi T, Toyama T, Taniguchi T, Tamaki Z, Isomura S, Miyagaki T, Mitsui H, Sato S.

J Dermatol. 2014 Dec;41(12):1113-4. doi: 10.1111/1346-8138.12688. Epub 2014 Nov 12. No abstract available.

PMID:
25389081
20.

Serum levels of anti-Fcγ receptor IIB/C antibodies are increased in patients with systemic sclerosis.

Kadono T, Tomita M, Tamaki Z, Sato S, Asano Y.

J Dermatol. 2014 Nov;41(11):1009-12. doi: 10.1111/1346-8138.12651.

PMID:
25346304
21.

Late-onset anaphylactic reactions following i.v. cyclophosphamide pulse in a patient with systemic sclerosis and systemic lupus erythematosus overlap syndrome.

Taniguchi T, Asano Y, Tamaki Z, Takahashi T, Ichimura Y, Toyama T, Kagami S, Mitsui H, Sato S.

J Dermatol. 2014 Oct;41(10):912-4. doi: 10.1111/1346-8138.12619. Epub 2014 Sep 16.

PMID:
25227247
22.

Serum levels of matrix metalloproteinase-13 in patients with eosinophilic fasciitis.

Asano Y, Ihn H, Jinnin M, Tamaki Z, Tamaki K, Sato S.

J Dermatol. 2014 Aug;41(8):746-8. doi: 10.1111/1346-8138.12563. Epub 2014 Jul 16.

PMID:
25041217
23.

Successful use of intravenous cyclophosphamide pulse therapy for interstitial lung disease in a patient with systemic sclerosis on hemodialysis.

Takahashi T, Asano Y, Sunaga R, Ichimura Y, Taniguchi T, Yamamoto M, Tamaki Z, Takekoshi T, Mitsui H, Sugaya M, Ohse T, Sato S.

J Dermatol. 2014 Jun;41(6):533-5. doi: 10.1111/1346-8138.12495. Epub 2014 May 10.

PMID:
24814462
24.

Successful experience of rituximab therapy for systemic sclerosis-associated interstitial lung disease with concomitant systemic lupus erythematosus.

Sumida H, Asano Y, Tamaki Z, Aozasa N, Taniguchi T, Takahashi T, Toyama T, Ichimura Y, Noda S, Akamata K, Miyazaki M, Kuwano Y, Yanaba K, Sato S.

J Dermatol. 2014 May;41(5):418-20. doi: 10.1111/1346-8138.12461.

PMID:
24801917
25.

FibronectinEDA promotes chronic cutaneous fibrosis through Toll-like receptor signaling.

Bhattacharyya S, Tamaki Z, Wang W, Hinchcliff M, Hoover P, Getsios S, White ES, Varga J.

Sci Transl Med. 2014 Apr 16;6(232):232ra50. doi: 10.1126/scitranslmed.3008264.

26.

Effects of the immunosuppressant rapamycin on the expression of human α2(I) collagen and matrix metalloproteinase 1 genes in scleroderma dermal fibroblasts.

Tamaki Z, Asano Y, Kubo M, Ihn H, Tada Y, Sugaya M, Kadono T, Sato S.

J Dermatol Sci. 2014 Jun;74(3):251-9. doi: 10.1016/j.jdermsci.2014.02.002. Epub 2014 Feb 17.

PMID:
24630239
27.

Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis.

Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Takata M, Ozeki A, Watanabe A, Kawarasaki S, Taniguchi T, Ichimura Y, Toyama T, Watanabe M, Hirata Y, Nagai R, Komuro I, Sato S.

Mod Rheumatol. 2014 Jan;24(1):106-11. doi: 10.3109/14397595.2013.854064.

PMID:
24261766
28.

Histological features of localized scleroderma 'en coup de sabre': a study of 16 cases.

Taniguchi T, Asano Y, Tamaki Z, Akamata K, Aozasa N, Noda S, Takahashi T, Ichimura Y, Toyama T, Sugita M, Sumida H, Kuwano Y, Miyazaki M, Yanaba K, Sato S.

J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1805-10. doi: 10.1111/jdv.12280. Epub 2013 Oct 10.

PMID:
24118540
29.

Varicella-like generalized pustulosis induced by adalimumab.

Suga H, Sugaya M, Tamaki Z, Yamamoto M, Tada Y, Sato S.

Int J Dermatol. 2013 Jul;52(7):890-2. doi: 10.1111/j.1365-4632.2011.05002.x. No abstract available.

PMID:
23789608
30.

Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis.

Hinchcliff M, Huang CC, Wood TA, Matthew Mahoney J, Martyanov V, Bhattacharyya S, Tamaki Z, Lee J, Carns M, Podlusky S, Sirajuddin A, Shah SJ, Chang RW, Lafyatis R, Varga J, Whitfield ML.

J Invest Dermatol. 2013 Aug;133(8):1979-89. doi: 10.1038/jid.2013.130. Epub 2013 Mar 14.

31.

Presence of desaturated hemoglobin enhances the contribution of blood cells to flow-mediated dilation in subjects with systemic sclerosis.

Amiya E, Takata M, Watanabe M, Takahashi T, Asano Y, Hatano M, Ozeki A, Watanabe A, Kawarasaki S, Tamaki Z, Taniguchi T, Ichimura Y, Toyama T, Nagai R, Sato S, Komuro I.

Int J Cardiol. 2013 Oct 3;168(3):3125-7. doi: 10.1016/j.ijcard.2013.04.046. Epub 2013 May 4. No abstract available.

PMID:
23647588
32.

Clinical correlation of brachial artery flow-mediated dilation in patients with systemic sclerosis.

Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Takata M, Ozeki A, Watanabe A, Kawarasaki S, Taniguchi T, Ichimura Y, Toyama T, Watanabe M, Hirata Y, Nagai R, Komuro I, Sato S.

Mod Rheumatol. 2013 Mar 30. [Epub ahead of print]

PMID:
23543079
33.

A synthetic PPAR-γ agonist triterpenoid ameliorates experimental fibrosis: PPAR-γ-independent suppression of fibrotic responses.

Wei J, Zhu H, Komura K, Lord G, Tomcik M, Wang W, Doniparthi S, Tamaki Z, Hinchcliff M, Distler JH, Varga J.

Ann Rheum Dis. 2014 Feb;73(2):446-54. doi: 10.1136/annrheumdis-2012-202716. Epub 2013 Mar 20.

34.

Toll-like receptor 4 signaling augments transforming growth factor-β responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma.

Bhattacharyya S, Kelley K, Melichian DS, Tamaki Z, Fang F, Su Y, Feng G, Pope RM, Budinger GR, Mutlu GM, Lafyatis R, Radstake T, Feghali-Bostwick C, Varga J.

Am J Pathol. 2013 Jan;182(1):192-205. doi: 10.1016/j.ajpath.2012.09.007. Epub 2012 Nov 7.

35.

The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy.

Fang F, Liu L, Yang Y, Tamaki Z, Wei J, Marangoni RG, Bhattacharyya S, Summer RS, Ye B, Varga J.

Arthritis Res Ther. 2012 Oct 23;14(5):R229. doi: 10.1186/ar4070.

36.

Dynamics of serum angiopoietin-2 levels correlate with efficacy of intravenous pulse cyclophosphamide therapy for interstitial lung disease associated with systemic sclerosis.

Takahashi T, Asano Y, Akamata K, Aozasa N, Taniguchi T, Noda S, Masui Y, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

Mod Rheumatol. 2013 Sep;23(5):884-90. doi: 10.1007/s10165-012-0755-1. Epub 2012 Sep 13.

PMID:
22972016
37.

Clinical significance of monitoring serum adiponectin levels during intravenous pulse cyclophosphamide therapy in interstitial lung disease associated with systemic sclerosis.

Masui Y, Asano Y, Takahashi T, Shibata S, Akamata K, Aozasa N, Noda S, Taniguchi T, Ichimura Y, Toyama T, Tamaki Z, Sumida H, Yanaba K, Tada Y, Sugaya M, Sato S, Kadono T.

Mod Rheumatol. 2013 Mar;23(2):323-9. doi: 10.1007/s10165-012-0660-7. Epub 2012 May 19.

PMID:
22610787
38.

Clinical significance of serum decoy receptor 3 levels in patients with systemic sclerosis.

Yamada D, Asano Y, Takahashi T, Masui Y, Aozasa N, Akamata K, Noda S, Tamaki Z, Tada Y, Sugaya M, Sato S, Kadono T.

Eur J Dermatol. 2012 May-Jun;22(3):351-7. doi: 10.1684/ejd.2012.1702.

PMID:
22456116
39.

Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis.

Taniguchi T, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Takahashi T, Ichimura Y, Toyama T, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

J Rheumatol. 2012 Mar;39(3):539-44. doi: 10.3899/jrheum.110755. Epub 2012 Jan 15.

PMID:
22247367
40.

Clinical significance of serum retinol binding protein-4 levels in patients with systemic sclerosis.

Toyama T, Asano Y, Takahashi T, Aozasa N, Akamata K, Noda S, Taniguchi T, Ichimura Y, Sumida H, Tamaki Z, Masui Y, Tada Y, Sugaya M, Sato S, Kadono T.

J Eur Acad Dermatol Venereol. 2013 Mar;27(3):337-44. doi: 10.1111/j.1468-3083.2011.04413.x. Epub 2011 Dec 26.

PMID:
22211766
41.

Serum apelin levels: clinical association with vascular involvements in patients with systemic sclerosis.

Aozasa N, Asano Y, Akamata K, Noda S, Masui Y, Yamada D, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

J Eur Acad Dermatol Venereol. 2013 Jan;27(1):37-42. doi: 10.1111/j.1468-3083.2011.04354.x. Epub 2011 Nov 24.

PMID:
22112232
42.

Clinical significance of serum levels of secretory leukocyte protease inhibitor in patients with systemic sclerosis.

Aozasa N, Asano Y, Akamata K, Noda S, Masui Y, Tamaki Z, Tada Y, Sugaya M, Kadono T, Sato S.

Mod Rheumatol. 2012 Aug;22(4):576-83. doi: 10.1007/s10165-011-0553-1. Epub 2011 Nov 11.

PMID:
22075605
43.

Improvement of endothelial function in parallel with the amelioration of dry cough and dyspnea due to interstitial pneumonia by intravenous cyclophosphamide pulse therapy in patients with systemic sclerosis: a preliminary report of two cases.

Takahashi T, Asano Y, Amiya E, Hatano M, Tamaki Z, Ozeki A, Watanabe A, Kawarasaki S, Nakao T, Taniguchi T, Ichimura Y, Toyama T, Watanabe M, Hirata Y, Nagai R, Sato S.

Mod Rheumatol. 2012 Aug;22(4):598-601. doi: 10.1007/s10165-011-0545-1. Epub 2011 Oct 21.

PMID:
22015621
44.

Effects of bosentan on nondigital ulcers in patients with systemic sclerosis.

Taniguchi T, Asano Y, Hatano M, Tamaki Z, Tomita M, Kawashima T, Miyazaki M, Sumida H, Akamata K, Takahashi T, Ichimura Y, Toyama T, Sugita M, Noda S, Yao A, Kinugawa K, Sato S.

Br J Dermatol. 2012 Feb;166(2):417-21. doi: 10.1111/j.1365-2133.2011.10581.x. Epub 2011 Dec 5.

PMID:
21848685
45.

Bosentan: a novel therapy for leg ulcers in Werner syndrome.

Noda S, Asano Y, Masuda S, Miyagawa T, Sugita M, Yamamoto M, Kogure A, Tamaki Z, Mitsui H, Hoashi T, Sugaya M, Sato S.

J Am Acad Dermatol. 2011 Aug;65(2):e54-e55. doi: 10.1016/j.jaad.2011.03.013. No abstract available.

PMID:
21763553
46.

A case of systemic sclerosis with sarcoidosis.

Suga H, Asano Y, Tamaki Z, Yamamoto M, Sugaya M, Shimizu J, Sato S.

Acta Derm Venereol. 2011 Oct;91(6):718-20. doi: 10.2340/00015555-1155. No abstract available.

47.

Efficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three cases.

Tamaki Z, Asano Y, Hatano M, Yao A, Kawashima T, Tomita M, Kinugawa K, Nagai R, Sato S.

Mod Rheumatol. 2012 Feb;22(1):94-9. doi: 10.1007/s10165-011-0472-1. Epub 2011 Jun 3.

PMID:
21633912
48.

Lymphomatoid papulosis showing γδ T-cell phenotype.

Morimura S, Sugaya M, Tamaki Z, Takekoshi T, Sato S.

Acta Derm Venereol. 2011 Oct;91(6):712-3. doi: 10.2340/00015555-1145. No abstract available.

49.

Severe livedoid vasculopathy associated with antiphosphatidylserine-prothrombin complex antibody successfully treated with warfarin.

Noda S, Asano Y, Yamazaki M, Ichimura Y, Tamaki Z, Takekoshi T, Sugaya M, Sato S.

Arch Dermatol. 2011 May;147(5):621-3. doi: 10.1001/archdermatol.2011.106. No abstract available.

PMID:
21576587
50.

Significant attenuation of macrovascular involvement by bosentan in a patient with diffuse cutaneous systemic sclerosis with multiple digital ulcers and gangrene.

Ichimura Y, Asano Y, Hatano M, Tamaki Z, Takekoshi T, Kogure A, Tomita M, Kawashima T, Miyazaki M, Taniguchi T, Takahashi T, Mitsui H, Sugaya M, Yao A, Kinugawa K, Sato S.

Mod Rheumatol. 2011 Oct;21(5):548-52. doi: 10.1007/s10165-011-0436-5. Epub 2011 Mar 10.

PMID:
21547701

Supplemental Content

Loading ...
Support Center